Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GameStop Corp. (GME) vs Twist Bioscience Corp (TWST) Price & Performance

GameStop Corp.Trade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

GameStop Corp. vs Twist Bioscience Corp — how do they compare? GameStop Corp. trades at $18.61 (market cap $8.44B), while Twist Bioscience Corp trades at $124.55 (market cap $7.72B). The key difference: GameStop Corp. and Twist Bioscience Corp are close in size by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, GameStop Corp. nearer its low. Which is the better fit depends on your goals.

GMETWST
Market Cap
$8.44B$7.72B
Sector
Consumer CyclicalHealth
52-Week High
$27.69$124.88
52-Week Low
$18.79$24.16
Enterprise Value
$4.42B$7.65B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GameStop Corp.

GME trades at $18.57, down 1.2% with bearish technical signals from moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and a significant turnaround to profitability, achieving a 20.45% net income margin in 2025. Recent news highlights strategic shifts including potential partnership discussions with eBay instead of a full acquisition. Cash position strengthened to $4.77 billion following a $3.85 billion net cash inflow in 2025.

The outlook remains mixed with strong profitability improvements offset by bearish technical indicators and cautious analyst sentiment. Investment opportunity exists in the company's operational turnaround and cash-rich balance sheet, while risks include potential shareholder dilution from recent debt conversions and ongoing competitive pressures in the retail gaming sector.

Twist Bioscience Corp

TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.

The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About GameStop Corp.

Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.

Read more on GME

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST